Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ATTAIN-OSA trial 1 / trial 2

ATTAIN-OSA trial 1 / trial 2

Orforglipron · Obstructive sleep apnoea + obesity or overweight (no T2D)

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Orforglipron
Population
Obstructive sleep apnoea + obesity or overweight (no T2D)
Official title
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
completed · 2024-10 → 2026-07
Participants
712
Duration
52 weeks
Registry
NCT06649045

Outcomes in the indication

ATTAIN-OSA trial 1 / trial 2 Orforglipron · Obstructive sleep apnoea + obesity or overweight (no T2D) · 52 weeks · n = 712 abstract

AHI −13.2 (trial 1, no PAP) and −12.0 (trial 2, on PAP) events/h vs placebo at 52 weeks, treatment-regimen estimand; 6 of 7 key secondary end points significant.

MeasureDrugControlDifference (95 % CI)Status
Apnea-hypopnea index, change from baseline (treatment-regimen estimand) ATTAIN-OSA Trial 1, no PAP
week 52
−17.8−4.5−13.2 (−17.7 to −8.7) events/habstract
Apnea-hypopnea index, change from baseline (treatment-regimen estimand) ATTAIN-OSA Trial 2, on PAP
week 52
−17.3−5.3−12.0 (−17.1 to −6.9) events/habstract
Verbatim quotes (2)
  • Apnea-hypopnea index, change from baseline (treatment-regimen estimand)
    in trial 1, the mean AHI change was -17.8 for orforglipron compared with -4.5 for placebo (difference, -13.2 [95% CI, -17.7 to -8.7]; P < .001)
  • Apnea-hypopnea index, change from baseline (treatment-regimen estimand)
    In trial 2, the mean AHI change was -17.3 for orforglipron and -5.3 for placebo (difference, -12.0 [95% CI, -17.1 to -6.9]; P < .001)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ATTAIN-OSA trial 1 / trial 2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-osa-trial-1-trial-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.